Augmentin Dosing for Community-Acquired Pneumonia in Adults
For adults with community-acquired pneumonia and comorbidities (chronic heart, lung, liver, or renal disease; diabetes; alcoholism; malignancy; or asplenia), use Augmentin 875 mg/125 mg twice daily OR 500 mg/125 mg three times daily OR 2000 mg/125 mg twice daily (extended-release formulation), combined with a macrolide or doxycycline. 1
Patient Stratification and Dosing
Healthy Outpatients Without Comorbidities
- Augmentin is NOT the first-line choice for this population
- Plain amoxicillin 1 g three times daily is preferred (strong recommendation) 1
- Reserve Augmentin for patients with comorbidities (see below)
Outpatients With Comorbidities
Use one of these Augmentin regimens WITH a macrolide or doxycycline:
- Augmentin 875 mg/125 mg twice daily (most convenient), OR
- Augmentin 500 mg/125 mg three times daily, OR
- Augmentin 2000 mg/125 mg twice daily (extended-release formulation for enhanced pharmacokinetics)
Combination partner options:
- Azithromycin 500 mg day 1, then 250 mg daily, OR
- Clarithromycin 500 mg twice daily, OR
- Doxycycline 100 mg twice daily
The 2019 ATS/IDSA guidelines provide a strong recommendation with moderate-quality evidence for this combination therapy approach in patients with comorbidities 1.
Alternative Monotherapy Option
- Respiratory fluoroquinolone alone (levofloxacin 750 mg daily OR moxifloxacin 400 mg daily) is an acceptable alternative to Augmentin-based combination therapy (strong recommendation, moderate evidence) 1
Duration of Therapy
The 2026 ATS guidelines recommend shorter antibiotic courses based on clinical stability:
- Minimum 3 days for outpatients and hospitalized patients with nonsevere CAP who achieve clinical stability 2
- Continue until clinical stability is achieved, then stop (rather than arbitrary 5-7 day courses)
- 5 days or greater for severe CAP (strong recommendation) 2
Clinical stability criteria (ALL must be met):
- Temperature <37.8°C
- Heart rate <100 beats/minute
- Respiratory rate <24 breaths/minute
- SpO₂ >90% on room air (or baseline oxygen requirement)
- Systolic blood pressure >90 mmHg
- Normal mental status
Critical caveat: Assess stability daily—do not prescribe a fixed duration upfront. Many hospitalized patients (>50%) will NOT qualify for short courses due to comorbidities or delayed stability 2.
Evidence Supporting High-Dose Augmentin
The 2000 mg/125 mg twice-daily extended-release formulation is pharmacokinetically enhanced to maintain higher amoxicillin serum concentrations, providing coverage against Streptococcus pneumoniae with MICs up to 4 mg/L (penicillin-resistant strains) 3, 4.
- Clinical success rates: 91.5% at test of cure 3
- Bacteriological success: 96% for penicillin-resistant S. pneumoniae 4
- Well-tolerated with similar adverse event rates to standard dosing 3
Important Pitfalls to Avoid
Do NOT use Augmentin as monotherapy in patients with comorbidities—combination with macrolide/doxycycline is essential for atypical pathogen coverage 1
Do NOT use macrolide monotherapy in areas with >25% pneumococcal macrolide resistance (most of the United States) 1
Do NOT prescribe fixed 7-10 day courses—the 2026 guidelines emphasize daily reassessment and stopping at clinical stability 2
Ensure close follow-up when using 3-day courses—patients need clear instructions on signs of recurrence (fever, tachycardia, dyspnea, altered mental status) and established communication plans 2
Consider renal/hepatic function when determining effective treatment duration, particularly for patients with renal insufficiency 2
Take with food to minimize gastrointestinal intolerance and enhance clavulanate absorption 5
Severe CAP Considerations
For patients meeting severe CAP criteria (requiring ICU admission, vasopressors, or mechanical ventilation):
- Do NOT use short-course therapy—maintain ≥5 days of antibiotics 2
- Higher risk of treatment failure, resistant organisms, and disseminated infection necessitates longer treatment 2
- Recent data shows 83.5% AMC susceptibility in severe CAP isolates, rising to 90.9% in patients without recent antibiotic exposure 6